The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

SAP’s finance chief, Dominik Asam, hopes tariffs are a “wake-up call” that can kick-start Europe into building more tech ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...